Kidney effects of long-term tenofovir in hepatitis B
Treatments studied
Part of Infections, Kidney & urinary clinical trials.
This study looks at whether taking tenofovir for hepatitis B for more than five years affects kidney function. If you have hepatitis B and have been on this medicine long-term, this trial will help understand if your kidneys need monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with hepatitis B.
- You have taken tenofovir (TDF) continuously for more than 5 years.
- You do not have another liver disease besides hepatitis B.
- You do not have chronic kidney disease.
- You are not taking combination therapy for hepatitis B (e.g., interferon plus a nucleoside analogue, or more than one nucleoside analogue).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether taking tenofovir for a long time (more than five years) affects bone density in people with chronic hepatitis B. It may help doctors understand how to better monitor bone health during treatment.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This study looks at how the HIV medicine tenofovir (TAF) is processed by the body in people with advanced kidney disease. It aims to help doctors understand the right dose for patients with kidney problems.
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Hear when a new Chronic HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.